The global cell and gene therapy market size is calculated at USD 25.03 billion in 2025 and is forecasted to reach around USD 117.46 billion by 2034, accelerating at a CAGR of 18.7% from 2025 to 2034. The North America cell and gene therapy market size surpassed USD 10.59 billion in 2024 and is expanding at a CAGR of 18.9% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Market, by Therapy Type
8.1.1. Cell Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Gene Therapy
8.1.2.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy Market, by Therapeutic class
9.1.1. Cardiovascular Disease
9.1.1.1. Market Revenue and Forecast
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Genetic Disorder
9.1.3.1. Market Revenue and Forecast
9.1.4. Rare Diseases
9.1.4.1. Market Revenue and Forecast
9.1.5. Oncology
9.1.5.1. Market Revenue and Forecast
9.1.6. Oncology
9.1.6.1. Market Revenue and Forecast
9.1.7. Ophthalmology
9.1.7.1. Market Revenue and Forecast
9.1.8. Infectious Disease
9.1.8.1. Market Revenue and Forecast
9.1.9. Neurological Disorders
9.1.9.1. Market Revenue and Forecast
9.1.10. Others
9.1. 10.1. Market Revenue and Forecast
10.1. Cell and Gene Therapy Market, by Delivery Method
10.1.1. In Vivo
10.1.1.1. Market Revenue and Forecast
10.1.2. Ex vivo
10.1.2.1. Market Revenue and Forecast
11.1. Cell and Gene Therapy Market, by End-Users
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Cancer Care Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Others
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Therapeutic class
12.1.3. Market Revenue and Forecast, by Delivery Method
12.1.4. Market Revenue and Forecast, by End-Users
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Therapeutic class
12.1.5.3. Market Revenue and Forecast, by Delivery Method
12.1.5.4. Market Revenue and Forecast, by End-Users
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Therapeutic class
12.1.6.3. Market Revenue and Forecast, by Delivery Method
12.1.6.4. Market Revenue and Forecast, by End-Users
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Therapeutic class
12.2.3. Market Revenue and Forecast, by Delivery Method
12.2.4. Market Revenue and Forecast, by End-Users
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Therapeutic class
12.2.5.3. Market Revenue and Forecast, by Delivery Method
12.2.5.4. Market Revenue and Forecast, by End-Users
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Therapeutic class
12.2.6.3. Market Revenue and Forecast, by Delivery Method
12.2.6.4. Market Revenue and Forecast, by End-Users
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Therapeutic class
12.2.7.3. Market Revenue and Forecast, by Delivery Method
12.2.7.4. Market Revenue and Forecast, by End-Users
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Therapeutic class
12.2.8.3. Market Revenue and Forecast, by Delivery Method
12.2.8.4. Market Revenue and Forecast, by End-Users
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Therapeutic class
12.3.3. Market Revenue and Forecast, by Delivery Method
12.3.4. Market Revenue and Forecast, by End-Users
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Therapeutic class
12.3.5.3. Market Revenue and Forecast, by Delivery Method
12.3.5.4. Market Revenue and Forecast, by End-Users
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Therapeutic class
12.3.6.3. Market Revenue and Forecast, by Delivery Method
12.3.6.4. Market Revenue and Forecast, by End-Users
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Therapeutic class
12.3.7.3. Market Revenue and Forecast, by Delivery Method
12.3.7.4. Market Revenue and Forecast, by End-Users
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Therapeutic class
12.3.8.3. Market Revenue and Forecast, by Delivery Method
12.3.8.4. Market Revenue and Forecast, by End-Users
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Therapeutic class
12.4.3. Market Revenue and Forecast, by Delivery Method
12.4.4. Market Revenue and Forecast, by End-Users
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Therapeutic class
12.4.5.3. Market Revenue and Forecast, by Delivery Method
12.4.5.4. Market Revenue and Forecast, by End-Users
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Therapeutic class
12.4.6.3. Market Revenue and Forecast, by Delivery Method
12.4.6.4. Market Revenue and Forecast, by End-Users
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Therapeutic class
12.4.7.3. Market Revenue and Forecast, by Delivery Method
12.4.7.4. Market Revenue and Forecast, by End-Users
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Therapeutic class
12.4.8.3. Market Revenue and Forecast, by Delivery Method
12.4.8.4. Market Revenue and Forecast, by End-Users
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Therapeutic class
12.5.3. Market Revenue and Forecast, by Delivery Method
12.5.4. Market Revenue and Forecast, by End-Users
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Therapeutic class
12.5.5.3. Market Revenue and Forecast, by Delivery Method
12.5.5.4. Market Revenue and Forecast, by End-Users
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Therapeutic class
12.5.6.3. Market Revenue and Forecast, by Delivery Method
12.5.6.4. Market Revenue and Forecast, by End-Users
13.1. Alnylam Pharmaceuticals Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amgen Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Biogen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CORESTEM Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Dendreon Pharmaceuticals LLC.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Helixmith Co. Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. JCR Pharmaceuticals Co. Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Kolon TissueGene Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample